Litcius/Paper detail

Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure

Tai‐Chung Lam, K. C. TSANG, Cheuk‐Wai Choi, Victor Lee, Ka On Lam, Chi‐Leung Chiang, T.H. So, Wing‐Lok Chan, S.F. Nyaw, F. Lim, Joseph Lau, Jeannie Chik, Feng‐Ming Kong, A.W. Lee

2021Lung Cancer71 citationsDOI

Topics & Concepts

MedicineAtezolizumabPemetrexedInternal medicineCarboplatinOsimertinibRegimenLung cancerBevacizumabOncologyAdverse effectChemotherapyCancerEpidermal growth factor receptorErlotinibImmunotherapyNivolumabCisplatinLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure | Litcius